HeartBeam (Nasaq:BEAT) announced today that it received a key patent relating to AI capabilities for its AIMIGo system.
The U.S. Patent and Trademark Office (USPTO) issued the allowance for a patent titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” The patent describes a system that combines recorded cardiac signals from AIMIGo with the patient’s symptoms and cardiac risk factors. Together, this calculates a cardiac risk score to provide simplified diagnostic information and actionable instructions.
Santa Clara, California-based HeartBeam said this aims to replicate the decision-making process of a physician assessing cardiac symptoms. However, with AIMIGo, it occurs remotely and in an automated manner.
HeartBeam developed AIMIGo as a personal, portable vector electrocardiogram (VECG) system. It assists patients and clinicians in assessing cardiac symptoms. It utilizes a reusable, credit card-sized VECG recording device and cloud-based software. The system can deliver critical data to clinicians in real-time outside of a medical setting.
Its 12-lead 3D vector electrocardiogram (ECG) device pairs with a smartphone app and cloud-based diagnostic software system. The system can facilitate remote heart attack detection. HeartBeam submitted AIMIGo for FDA 510(k) clearance last week.
“We believe this patent will further our effort to create a dominant IP position in the area of ambulatory VECG. We believe that coupling AI with the highest resolution ambulatory ECG device available will have the power to deliver unprecedented diagnostic capability for patients experiencing acute cardiac symptoms, which will ultimately lead to improved care and saved lives,” said Branislav Vajdic HeartBeam CEO and founder.
“This patent will be followed by an aggressive IP development effort with PatentVest as we refine our algorithms, systems and devices.”